1. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF (1997) A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80: 401–412
2. Aoki K, Kurooka M, Chen J-J, Petryniak J, Nabel EG, Nabel GJ (2001) Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity. Nature Immunology 2: 333–337
3. Arai H, Chan SY, Bishop DK, Nabel GJ (1997a) Inhibition of the alloantibody response by CD95 ligand. Nat Med 3: 843–848
4. Arai H, Gordon D, Nabel EG, Nabel GJ (1997b) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94: 13862–13867
5. Benou E, Fontenay-Roupie M, Quarck R, McKenzie F, Levy-Toledano S, Tobelem G, Bryckaert M (1996) Transforming growth factor 131 inhibits mitogen-activated protein kinase induced by basic fibroblast growth factor in smooth muscle cells. Biochem J 316:167–173